Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Morningstar Management Behind the Moat Conference (Virtual) Transcript

Sep 30, 2020 / 05:00PM GMT
Karen Andersen;Brian R. Mueller
Morningstar Inc., Research Division - Sector Strategist;

Hi, everyone. Good morning or good afternoon, and welcome to our session with BioMarin. I'm Karen Andersen, and I cover biotech as a health care strategist at Morningstar. So BioMarin, in case you're not familiar, they've built a business with several approved treatments for rare diseases, and they have a growing gene therapy pipeline as well. So we've awarded them a narrow moat rating due to their competitive advantages in their spaces.

And we're joined today by Brian Mueller. So Brian has been at BioMarin for close to 18 years, I think, and is currently serving as the firm's Chief Financial Officer. Traci McCarty is also here. She's VP of Investor Relations. So Brian planned a short presentation. And after that, we can follow up with a few questions until we hit our 45-minute mark. Please feel free to submit questions. You can type them into the platform, and I can incorporate them into the discussion with Brian after the slide. So with that, I'll turn it over to Brian.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot